Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 107

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 107
---
 currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. If the U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result in decreased revenues and operating expenses. We may not be able to offset adverse foreign currency impact with increased revenues. Even with this strategy in place to mitigate balance sheet foreign currency risk, we will not eliminate our exposure to foreign exchange rate fluctuations on our financial results. We are subject to risks related to taxation in multiple jurisdictions. We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments based on interpretations of existing tax laws or regulations are required in determining the provision for income taxes. Our effective income tax rate could be adversely affected by various factors, including, but not limited to, changes in the mix of earnings in tax jurisdictions with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in existing tax policies, laws, regulations, or rates, changes in the level of non -deductibleexpenses (including share -basedcompensation), location of operations, changes in our future levels of research and development spending, mergers and acquisitions, or the result of examinations by various tax authorities. Although we believe our tax estimates are reasonable, if the IRS or other taxing authority disagrees with the positions taken on our tax returns, we could have additional tax liability, including interest and penalties. If material, payment of such additional amounts upon final adjudication of any disputes could have a material impact on our business, results of operations, financial condition and growth prospects. Our inability to manage growth could harm our business. In connection with the commercialization of our tests, we have added, and expect to continue to add personnel to certain areas of our business areas including research and development, laboratory operations, quality assurance, compliance, investor relations, reporting, marketing, other financial and legal functions and sales, among others. Further, as we build our commercialization efforts and expand research and development activities for new products and services, and effect potential acquisitions, the scope and complexity of our operations is increasing significantly. As a result of our growth, our operating expenses, our research and development, which includes our Argentine Wet -Laband our product development, and capital requirements will also increase, and we expect that they will continue to increase significantly. We may introduce a hybrid approach to our laboratory operations, with our Argentine Wet -Laband a main laboratory in Mexico; and may send samples to our laboratories or send products for processing